Abbott Laboratories ABT recently received the FDA go-ahead for its Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. BOSTON — At 3 years, the Amplatzer Amulet device ...

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

Please provide your email address to receive an email when new articles are posted on . In a head-to-head comparison of two left atrial appendage closure devices for patients with atrial fibrillation, ...

ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

Photo Credit: Hermiller J. AMULET: device characteristics, procedural technique, clinical outcomes, and ongoing studies. Presented at: TCT 2019. The US Food and Drug Administration has approved the ...